Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.35 |
| ▸ | CDK2 | P24941 | 8/20 | 0.35 |
| ▸ | CCNK | O75909 | 8/20 | 0.34 |
| ▸ | CCND3 | P30281 | 8/20 | 0.34 |
| ▸ | CDK9 | P50750 | 8/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.34 |
| ▸ | INSR | P06213 | 3/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | BCL6 | P41182 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24327013 | 0.76 | INSR (0.39) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL29661346 | 0.76 | INSR (0.39) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL4099937 | 0.74 | CXCR2 (0.44) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL29661395 | 0.72 | MAP4K1 (0.38) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL24327605 | 0.72 | MAP4K1 (0.38) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL30141686 | 0.71 | CCNA2 (0.41) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL2062564 | 0.71 | IGF1R (0.54) | CCNA2CDK2CCNKCCND3CDK9 | |
| SCHEMBL25005398 | 0.70 | NOTUM (0.47) | METALKMAPK3 | |
| SCHEMBL8901220 | 0.69 | ADRA2A (0.38) | HTR1AADRA2ASLC6A2SLC6A4 | |
| SCHEMBL24620238 | 0.68 | MAPK10 (0.43) | CCNA2CDK2CCNKCCND3CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017041771-A1 | PROCESS FOR THE PREPARATION OF CERITINIB USING \"IN SITU\" PREPARED 5-METHYL-2-(1 -METHYLETHOXY)-4-(4-PIPERIDINYL)-BENZENAMINE MONOHYDROCHLORIDE (1 :1 ) AS AN INTERMEDIATE | ZENTIVA, K.S. (CZ) | 2017-03-16 | — | — | WO | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | CCNA2 289/4885CDK2 43/4885CCNK 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.